Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • COVID-19
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • Topics A-Z
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • COVID-19
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • Topics A-Z
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in
  • Log out

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
  • Log out
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

August 01, 1996; 47 (2) ARTICLES

Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease

R. L. Albin, S. Minoshima, C. J. D'Amato, K. A. Frey, D. A. Kuhl, A.A.F. Sima
First published August 1, 1996, DOI: https://doi.org/10.1212/WNL.47.2.462
R. L. Albin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. Minoshima
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. J. D'Amato
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
K. A. Frey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. A. Kuhl
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A.A.F. Sima
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease
R. L. Albin, S. Minoshima, C. J. D'Amato, K. A. Frey, D. A. Kuhl, A.A.F. Sima
Neurology Aug 1996, 47 (2) 462-466; DOI: 10.1212/WNL.47.2.462

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
112

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Abstract

We report six demented individuals with pathologically verified diffuse Lewy body disease (DLBD) studied with fluoro-deoxyglucose positron emission tomography (FDG-PET). Three subjects had pure DLBD and three subjects had combined DLBD and Alzheimer's disease (DLBD-AD) pathology. FDG-PET revealed evidence of diffuse cerebral hypometabolism in both pure DLBD and DLBD-AD with marked declines in association cortices with relative sparing of subcortical structures and primary somatomotor cortex, a pattern reported previously in AD. Unlike AD, however, these subjects also had hypometabolism in the occipital association cortex and primary visual cortex. These findings indicate the presence of diffuse cortical abnormalities in DLBD and suggest that FDG-PET may be useful in discriminating DLBD from AD antemortem.

NEUROLOGY 1996;47: 462-466

Diffuse Lewy body disease (DLBD) is a dementing process characterized pathologically by the occurrence of Lewy bodies in subcortical, allocortical, and neocortical structures. [1-7] This disorder is described in a pure form and in conjunction with Alzheimer's disease (AD) pathology. [8,9] DLBD is recognized increasingly as a common cause of dementia, with autopsy series of demented individuals reporting a frequency of DLBD ranging from 13 to 26%. [2,3,7] If these estimates reflect true prevalence, DLBD would be the second most common form of dementia in the developed world. The epidemiology, complete clinical spectrum, and pathogenesis of DLBD are unknown.

DLBD is presently a pathologic diagnosis. Clinical criteria have been described for the antemortem diagnosis of DLBD but these criteria have not been tested in a prospective study. [10,11] The development of methods to diagnose DLBD accurately prior to death would facilitate the study of DLBD. Noninvasive imaging with fluoro-deoxyglucose positron emission tomography (FDG-PET) may be a useful method for diagnosis of AD and other dementing disorders. We report results in demented individuals with pathologically verified DLBD who were prospectively studied with FDG-PET.

Results.

Clinical.

Clinical data are summarized in Table 1.

View this table:
  • View inline
  • View popup
  • Download powerpoint

Table 1. Clinical characteristics of DLBD and DLBD-AD patients

PET studies.

In five patients, [sup 18 F]-2-fluoro-deoxy-D-glucose (FDG) PET images were obtained using a Siemens ECAT 931/08-12 imager (CTI, Knoxville, TN) as described previously. [12-14] Arterial sampling was done in three patients for measurement of the arterial input function. One patient was studied using a Cyclotron Corporation PC4600A imager with five sections obtained at 11.5 mm separation. The protocol allowed coverage of 20 cm with section separation of 5 mm using interleaved images. The in-plane resolution was 12 mm at full-width-at-half-maximum. PET image sets obtained with arterial input function measurements were converted to quantitative glucose metabolic rate with a standard single-image approach. [15]

Reconstructed image sets were transformed into the stereotaxic coordinate system and cerebral metabolic activity was extracted into the stereotaxic surface projection format as described previously. [12,13] Regional activity was averaged using region-of-interest analysis for parietal cortex, temporal cortex, frontal cortex, occipital association cortex, anterior cingulate cortex, posterior cingulate cortex, primary somatomotor cortex, parahippocampal gyrus, thalamus, striatum, cerebellum, and pons. The locations of these regions were defined by standard stereotaxic coordinates. [13,16] Since some imaging was performed in a qualitative manner, regional metabolic values were normalized to pontine metabolic activity prior to subsequent data analysis. Analysis of results from three patients with quantitative studies revealed normal metabolic activity in the pons, consistent with prior studies and supporting normalization of this data set. [14] Normalized regional metabolic data were compared with a normal database as described previously. [13,17] Regional percent reductions of glucose metabolism of DLBD and DLBD-AD cases were transformed to Z scores using the formula [(individual regional value) - (control regional mean)/(control regional standard deviation)] to assess significance of reductions in glucose metabolism. Z scores (ZS) greater than 3, indicating regional values greater than 3 standard deviations from the control mean, were considered significant.

The normalized values indicated severe metabolic reductions in parietal (mean decrease 38%; ZS > 3), temporal (mean decrease 28%; ZS > 3), and frontal (mean decrease 28%; ZS > 3) association cortices, and in the posterior cingulate cortex (mean decrease 35%; ZS > 3). Regional metabolic activity in the primary sensorimotor cortex (mean decrease 20%; ZS < 3), thalamus (mean decrease 18%; ZS < 3), striatum (mean decrease 18%; ZS < 3), cerebellum (mean decrease 9%; ZS < 3), anterior cingulate cortex (mean decrease 22%; ZS < 3), and parahippocampal gyrus (mean decrease 13%; ZS < 3) was relatively preserved Figure 1. This profile was similar in both the DLBD and DLBD-AD groups and similar in magnitude and pattern to cerebral metabolic reductions noted previously in probable AD. [17-19] In addition, metabolic activities in the occipital association (mean decrease 32%; ZS > 3) and primary visual (mean decrease 32%; ZS > 3) cortices were markedly reduced (see Figure 1). The pattern and magnitude of regional metabolic reductions in primary visual and occipital association cortices were similar in both pure DLBD and DLBD-AD patients.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 1. Representative DLBD and AD + DLBD FDG-PET images. CMRglc maps represent regional glucose uptake normalized to pontine glucose uptake. The higher the number, the greater the degree of FDG uptake. Note reduced FDG uptake in the frontal, parietal, and occipital cortices. Z-score maps represent Z scores relative to control data base. The higher the Z score, the greater the deviation from normal. In this case, high Z scores represent reductions in FDG uptake. In both DLBD and AD + DLBD images, frontal, parietal, and occipital cortices have markedly abnormal Z scores.

Neuropathology.

At autopsy, brains were hemisected and one hemisphere frozen and stored at -70 degrees C. The remaining hemisphere was fixed in neutral buffered formalin. The fixed hemisphere was sectioned coronally and inspected for gross changes. A total of 46 anatomic sites from cerebral cortex, subcortical nuclei, the hippocampal formation, and cerebellum were examined. Paraffin sections were stained with cresyl violet-luxol fast blue-eosin (CV-LFB-E), phosphotungstic acid-hematoxylin (PTAH), and Bielschowsky's silver impregnation. For identification of Lewy bodies, sections were immunostained with a polyclonal rabbit anti-human ubiquitin antiserum (Dako, Carpenteria, CA). [20]

There was no gross atrophy of the cortical mantle or white matter. The frontal, temporal, and occipital lobes appeared within normal limits. Cerebella and brainstems appeared normal in all cases with the exception of mild substantia nigra pallor.

With light microscopy, both pure DLBD and DLBD-AD cases exhibited mild to moderately severe neocortical degeneration consisting of neuronal loss and gliosis. In both groups, neocortical involvement was most severe in the entorhinal cortex, followed by anterior cingulate and parietal cortices. In the three pure DLBD cases, posterior cingulate and occipital cortices showed no pathologic changes but DLBD-AD showed moderate involvement of both these regions. In the hippocampus, both groups showed the most severe changes in CA4, followed by subiculum, CA3, CA2, and CA1. The piriform cortex, amygdala, and anterior hypothalamus showed moderately severe changes with no difference between pure DLBD and DLBD-AD. Moderate neuronal loss and gliosis of the basal nucleus of Meynert did not differ between the DLBD and DLBD-AD groups. In both groups, marked degenerative changes were present in the ventral tegmental area.

In DLBD-AD cases, neurofibrillary tangles and senile plaques, exceeding the number required to satisfy diagnostic criteria, [21] were found in the frontal, parietal, temporal, entorhinal, and posterior cingulate cortices and within the amygdala. Cortical Lewy bodies were demonstrated in the entorhinal, anterior cingulate, and insular cortices of both DLBD and DLBD-AD cases Figure 2. The overall distribution did not differ between DLBD and DLBD-AD cases although there was a trend toward a greater density of Lewy bodies in DLBD than in DLBD-AD cases.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 2. Ubiquitin-immunoreactive Lewy bodies (arrows) in the anterior cingulate of a patient with pure DLBD. Magnification 240 times, before 75% reduction.

Discussion.

The clinicopathologic spectrum of Lewy body-associated disorders varies from idiopathic Parkinson's disease with Lewy body expression restricted to subcortical nuclei to so-called ``pure'' DLBD, in which both neocortical and subcortical Lewy bodies are abundant and the clinical picture is dominated by dementia. Neocortical Lewy body pathology is often associated with some pathologic features of AD, especially the occurrence of senile plaques. [2,3,7,9]

McKeith et al. [10,11] have proposed clinical criteria for DLBD (which they term senile dementia of Lewy body type) and have demonstrated good levels of sensitivity, specificity, and interrater reliability, but these criteria have not yet been verified prospectively. The development of imaging or other objective measures to supplement clinical criteria would be useful in studying DLBD.

The patients described in this report exhibited clinical features described previously as useful in distinguishing DLBD from other types of dementia, including fluctuating cognitive impairment, visual hallucinations, and parkinsonism. [10,11] As with previous reports of DLBD, however, there is not a uniform clinical presentation. Two of our patients (cases 1 and 3) presented with parkinsonism rather than cognitive symptoms. The remainder presented with dementia and some, but not all, developed parkinsonism later in their course.

All patients had evidence of hypometabolism in numerous brain regions. Marked reductions were present in many cortices with relative sparing of primary sensorimotor and subcortical regions, a pattern associated previously with AD. In addition, there was evidence of marked hypometabolism in the occipital cortex, a finding not noted in most studies of AD. [13,18] Some prior FDG-PET studies have documented occipital hypometabolism in patients suffering from Parkinson's disease with dementia, [22] raising the possibility that the patients examined in these prior studies suffered from DLBD. The observation of occipital hypometabolism in DLBD has implications for the use of FDG-PET in studies of dementing illnesses. If DLBD is relatively common, then appropriate classification of demented patients as having DLBD or AD might be necessary for performance of clinical and therapeutic studies of demented patients. FDG-PET may be useful in this context or may allow refinement of clinical criteria to discriminate DLBD and AD. Larger numbers of subjects will need to be studied to confirm or refute these conjectures and more widely available techniques such as HMPAO-SPECT imaging may be useful in evaluating these questions.

Occipital hypometabolism may not be unique to DLBD. A subgroup of AD patients has marked pathology involving both primary visual cortex and occipital association cortex. [23-26] This AD subgroup presents clinically with Balint's syndrome and other complex disturbances of vision. FDG-PET studies of a small number of these AD patients indicate the presence of primary visual cortex and occipital association cortex hypometabolism. [27,28] Differentiation of this visual form of AD from DLBD or DLBD-AD may be possible on clinical grounds.

Widespread changes in cortical metabolism in patients with pure DLBD, despite the relatively restricted distribution of Lewy body pathology, is direct evidence of diffuse cortical dysfunction. Neocortical Lewy bodies tend to occur in the cingulate cortex, entorhinal cortex, insular cortex, frontal cortex, and amygdala, suggesting preferential involvement of limbic cortices. [1,4-8] Our FDG-PET data indicate widespread functional impairment of the cortical mantle in both pure DLBD and DLBD-AD without a definite correlation with the distribution of Lewy body pathology. The anterior cingulate cortex, a region that consistently shows a high density of Lewy bodies, had relatively preserved cerebral metabolism. Some cortical regions without evident major pathology, such as the posterior cingulate cortex and occipital cortex, demonstrated major reductions in metabolic activity. The pattern of cortical hypometabolism in DLBD may reflect diachisis due to disruption of intracortical connections.

Several lines of evidence suggest that DLBD is a distinct clinicopathologic entity. The unique composition and distribution of Lewy bodies, the characteristic pattern of neuronal loss, the possible existence of characteristic clinical features, and possibly distinctive neurochemical changes all serve to differentiate DLBD from AD and other dementias. [29-35] Our data suggest that DLBD is characterized also by a relatively distinctive pattern of cortical metabolic disturbances.

Acknowledgments

We thank Kris Wernette and Bruno Giordani for assistance. We thank the anonymous reviewers and Neurology editorial staff for constructive criticism.

  • Copyright 1996 by Advanstar Communications Inc.

REFERENCES

  1. 1.↵
    Kosaka K. Dementia and neuropathology in Lewy body disease. Adv Neurol 1993;60:456-463.
    OpenUrl
  2. 2.↵
    Perry PH, Irving D, Blessed G, Fairbairn A, Perry EK. Senile dementia of Lewy body type. J Neurol Sci 1990;95:119-139.
    OpenUrl
  3. 3.
    Byrne J, Lennox G, Lowe J, Godwin-Austen RB. Diffuse Lewy body disease: clinical features in 15 cases. J Neurol Neurosurg Psychiatry 1989;52:709-717.
    OpenUrlFREE Full Text
  4. 4.
    Gibb RG, Esiri MM, Lees AJ. Clinical and pathological features of diffuse cortical Lewy body disease (Lewy body dementia). Brain 1985;110:1131-1153.
    OpenUrl
  5. 5.
    Pollanen MS, Dickson DW, Bergeron C. Pathology and biology of the Lewy body. J Neuropathol Exp Neurol 1993;52:183-191.
    OpenUrlPubMed
  6. 6.
    Sima AAF, Clark AW, Sternberger NA, Sternberger LA. Lewy body dementia without Alzheimer changes. Can J Neurol Sci 1986;13:490-497.
    OpenUrl
  7. 7.
    Crystal HA, Dickson DW, Lizardi JE, Davies P, Wolfson LI. Antemortem diagnosis of diffuse Lewy body disease. Neurology 1990;40:1523-1528.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    Lennox G, Lowe J, Landon M, Byrne E, Mayer RJ, Godwin-Austen RB. Diffuse Lewy body disease: correlative neuropathology using anti-ubiquitin immunocytochemistry. J Neurol Neurosurg Psychiatry 1989;52:1236-1247.
    OpenUrlAbstract/FREE Full Text
  9. 9.
    Hansen LA, Masliah E, Galasko D, Terry RD. Plaque-only Alzheimer disease is usually the Lewy body variant, and vice versa. J Neuropathol Exp Neurol 1993;52:648-654.
    OpenUrl
  10. 10.↵
    McKeith IG, Perry RH, Fairbairn AF, Jabeen S, Perry EK. Operational criteria for senile dementia of Lewy body type (SDLT). Psychol Med 1992;22:911-922.
    OpenUrl
  11. 11.
    McKeith IG, Fairbairn AF, Bothwell RA, et al. Evaluation of the predictive validity and inter-rater reliability of clinical diagnostic criteria for senile dementia of Lewy body type. Neurology 1994;44:872-877.
    OpenUrl
  12. 12.↵
    Minoshima S, Koeppe RA, Frey KA, Kuhl DE. Anatomical standardization: linear scaling and nonlinear warping of functional brain images. J Nucl Med 1994;35:1528-1537.
    OpenUrlPubMed
  13. 13.↵
    Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A new diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of [sup 18 F]FDG. J Nucl Med 1995;36:1238-1248.
    OpenUrlPubMed
  14. 14.↵
    Minoshima S, Frey KA, Foster NL, Kuhl DE. Preserved pontine glucose metabolism in Alzheimer's disease: a reference region for functional brain image analysis. J Comput Assist Tomogr 1995;19:541-547.
    OpenUrl
  15. 15.↵
    Hutchins GD, Holden JE, Koeppe RA, Halama JR, Gatley SJ, Nickles RJ. Alternative approach to single scan estimation of cerebral glucose metabolic rate using glucose analogs, with particular application to ischemia. J Cereb Blood Flow Metab 1984;4:35-40.
    OpenUrlPubMed
  16. 16.
    Talairach J, Tournoux P. Co-planar stereotaxic atlas of the human brain. Stuttgart: Thieme, 1988.
  17. 17.↵
    Minoshima S, Foster NL, Kuhl DE. Posterior cingulate cortex in Alzheimer's disease. Lancet 1994;344:895.
    OpenUrl
  18. 18.
    Herholz K, Adams R, Kessler J, Szelies B, Grond M, Heiss WD. Criteria for the diagnosis of Alzheimer's disease with positron emission tomography. Dementia 1990;1:156-164.
    OpenUrlPubMed
  19. 19.
    Duara R, Grady C, Haxby J, et al. Positron emission tomography in Alzheimer's disease. Neurology 1986;36:879-887.
    OpenUrl
  20. 20.↵
    Lennox G, Lowe J, Morrell K, Landon M, Mayer RJ. Antiubiquitin immunocytochemistry is more sensitive than conventional techniques in the detection of diffuse Lewy body disease. J Neurol Neurosurg Psychiatry 1989;52:67-71.
    OpenUrlFREE Full Text
  21. 21.↵
    Khachaturian ZS. Diagnosis of Alzheimer's disease. Arch Neurol 1985;42:1097-1105.
    OpenUrl
  22. 22.↵
    Goto I, Taniwaki T, Hosokawa S, Otsuka M, Ichiya Y, Ichimaya A. Positron emission tomography studies in dementia. J Neurol Sci 1993;114:1-6.
    OpenUrlCrossRefPubMed
  23. 23.↵
    Hof PR, Bouras C, Constantinidis J, Morrison JH. Selective disconnection of specific visual association pathways in cases of Alzheimer's disease presenting with Balint's syndrome. J Neuropathol Exp Neurol 1990;49:168-184.
    OpenUrl
  24. 24.
    Hof PR, Bouras C, Constantinidis J, Morrison JH. Balint's syndrome in Alzheimer's disease: specific disruption of the occipitoparietal visual pathway. Brain Res 1989;493:368-375.
    OpenUrl
  25. 25.
    Levine DN, Lee JM, Fisher CM. The visual variant of Alzheimer's disease: a clinicopathologic case study. Neurology 1993;43:305-313.
    OpenUrl
  26. 26.
    Berthier ML, Leiguarda R, Starkstein SE, Sevlever G, Taratuto AL. Alzheimer's disease in a patient with posterior cortical atrophy. J Neurol Neurosurg Psychiatry 1991;54:1110-1111.
    OpenUrlFREE Full Text
  27. 27.↵
    Kiyosawa M, Bosley TM, Chawluk J, et al. Alzheimer's disease with prominent visual symptoms. Ophthalmology 1989;96:1077-1086.
    OpenUrlPubMed
  28. 28.
    Pietrini P, Freo U, Grady CL, et al. A longitudinal positron emission tomography study of cerebral glucose metabolism in patients with Alzheimer's disease and prominent visual impairment. Adv Biosciences 1993;87:69-71.
    OpenUrl
  29. 29.↵
    Perry EK, McKeith I, Thompson P, et al. Topography, extent, and clinical relevance of neurochemical deficits in dementia of Lewy body type, Parkinson's disease, and Alzheimer's disease. Ann NY Acad Sci 1991;640:197-202.
    OpenUrlPubMed
  30. 30.
    Lippa CF, Smith TW, Swearer JM. Alzheimer's disease and Lewy body disease: a comparative clinicopathological study. Ann Neurol 1994;35:81-88.
    OpenUrl
  31. 31.
    Dickson DW, Schmidt ML-Y, Lee VM-Y, Zhao ML, Yen S-H, Trojanowski JQ. Immunoreactivity profile of hippocampal CA2/3 neurites in diffuse Lewy body disease. Acta Neuropathol (Berl) 1994;87:269-276.
    OpenUrl
  32. 32.
    Harrington CR, Perry RH, Perry EK, et al. Senile dementia of Lewy body type and Alzheimer type are biochemically distinct in terms of paired helical filaments and hyperphosphorylated tau protein. Dementia 1994;5:215-228.
    OpenUrl
  33. 33.
    Dickson DW, Crystal H, Mattiace LA, et al. Diffuse Lewy body disease: light and electron microscopic immunocytochemistry of senile plaques. Acta Neuropathol (Berl) 1989;78:572-584.
    OpenUrl
  34. 34.
    Perry EK, Marshall E, Thompson P, et al. Monoaminergic activities in Lewy body dementia: relation to hallucinosis and extrapyramidal features. J Neural Transm Park Dis Dement Sect 1993;6:167-177.
    OpenUrlPubMed
  35. 35.
    Smith MC, Mallory M, Hansen LA, Ge N, Masliah E. Fragmentation of the neuronal cytoskeleton in the Lewy body variant of Alzheimer's disease. Neuroreport 1995;6:673-676.
    OpenUrlPubMed

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • Results.
    • Discussion.
    • Acknowledgments
    • REFERENCES
  • Figures & Data
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • Neurology: Education
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2022 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise